$60,000 of HONEYWELL INTERNATIONAL lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"General outreach"
You can find more data on corporate lobbying on Quiver Quantitative.
HON Congressional Stock Trading
Members of Congress have traded $HON stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $HON stock by members of Congress over the last 6 months:
- SENATOR ANGUS S. KING JR. purchased up to $15,000 on 12/29.
- REPRESENTATIVE DEBBIE DINGELL sold up to $50,000 on 11/24.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 11/18.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 09/25.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
HON Insider Trading Activity
HON insiders have traded $HON stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $HON stock by insiders over the last 6 months:
- GRACE LIEBLEIN has made 0 purchases and 3 sales selling 5,847 shares for an estimated $1,425,089.
- ROBERT D. MAILLOUX (Vice President & Controller) sold 5,274 shares for an estimated $1,260,486
- D SCOTT DAVIS sold 2,367 shares for an estimated $568,080
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HON Hedge Fund Activity
We have seen 1,112 institutional investors add shares of HON stock to their portfolio, and 1,428 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J. STERN & CO. LLP added 52,975,716 shares (+22704.6%) to their portfolio in Q4 2025, for an estimated $10,335,032,434
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 9,237,983 shares (-71.4%) from their portfolio in Q4 2025, for an estimated $1,802,238,103
- SG AMERICAS SECURITIES, LLC added 4,046,879 shares (+36520.9%) to their portfolio in Q4 2025, for an estimated $789,505,624
- BLACKROCK, INC. added 3,582,757 shares (+7.3%) to their portfolio in Q4 2025, for an estimated $698,960,063
- BARCLAYS PLC removed 3,189,870 shares (-34.8%) from their portfolio in Q4 2025, for an estimated $622,311,738
- NOMURA HOLDINGS INC removed 3,141,472 shares (-80.0%) from their portfolio in Q4 2025, for an estimated $612,869,772
- JPMORGAN CHASE & CO removed 2,457,297 shares (-23.8%) from their portfolio in Q4 2025, for an estimated $479,394,071
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HON Analyst Ratings
Wall Street analysts have issued reports on $HON in the last several months. We have seen 5 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 01/30/2026
- JP Morgan issued a "Overweight" rating on 01/30/2026
- Citigroup issued a "Buy" rating on 01/12/2026
- B of A Securities issued a "Underperform" rating on 11/18/2025
- TD Cowen issued a "Buy" rating on 11/10/2025
- RBC Capital issued a "Outperform" rating on 10/27/2025
To track analyst ratings and price targets for HON, check out Quiver Quantitative's $HON forecast page.
HON Price Targets
Multiple analysts have issued price targets for $HON recently. We have seen 12 analysts offer price targets for $HON in the last 6 months, with a median target of $250.0.
Here are some recent targets:
- Chris Snyder from Morgan Stanley set a target price of $245.0 on 03/12/2026
- Sheila Kahyaoglu from Jefferies set a target price of $245.0 on 03/04/2026
- Julian Mitchell from Barclays set a target price of $275.0 on 03/04/2026
- Nigel Coe from Wolfe Research set a target price of $293.0 on 02/27/2026
- Andrew Kaplowitz from Citigroup set a target price of $265.0 on 01/30/2026
- Deane Dray from RBC Capital set a target price of $268.0 on 01/30/2026
- Stephen Tusa from JP Morgan set a target price of $260.0 on 01/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
